

| | |
|-------------------------------|---|
| STUDY TITLE | PROTECT-ICD Trial |
| STUDY POPULATION | Patient with Myocardial Infarction (MI) and impaired left ventricular systolic function |
| PRINCIPAL INVESTIGATOR | Datuk Dr. Razali Omar |
| STUDY COORDINATOR | Siti Nur 'Ain Mahamad Anuar Contact number 03 – 2617 8200 ext 8451 |
| START DATE | 5 Apr 2016 |
| END DATE | 5 Apr 2018 |
| INCLUSION | <ul style="list-style-type: none"> • Patient is <u>2 to 40 days</u> (inclusive) following an MI <ul style="list-style-type: none"> - STEMI or NSTEMI <p>And</p> <ul style="list-style-type: none"> • Patient has impaired left ventricular systolic function <ul style="list-style-type: none"> - LVEF 40% or less <p style="text-align: center;">OR</p> <ul style="list-style-type: none"> - LV dysfunction is “moderate”, “moderate to severe” or “severe” |
| EXCLUSION | <ul style="list-style-type: none"> • Age less than 18 or more than 85 • Pregnancy • Nursing home resident dependent on one or more activities of daily living • Significant non-cardiac co-morbidity with high likelihood of death within 1 year • Significant psychiatric illnesses that may be aggravated by device implantation • Intravenous drug abuse (ongoing) • Unresolved infection associated with risk for hematogenous seeding • Pre-existing ICD • Secondary prevention indication for an ICD • On the heart transplant list • Recurrent unstable angina despite revascularisation* • Congestive heart failure New York Heart Association class IV (not responding to treatment)* <p>**NOTE: patients who meet exclusion based on (11) or (12) can be reviewed again in 2-3 days and if symptoms have resolved or treatment performed can be re-considered for inclusion</p> |